Edwards Lifesciences Corporation $EW Stake Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,636,881 shares of the medical research company’s stock after acquiring an additional 35,997 shares during the period. Dimensional Fund Advisors LP’s holdings in Edwards Lifesciences were worth $291,234,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank acquired a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $803,686,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Viking Global Investors LP bought a new position in Edwards Lifesciences during the 3rd quarter valued at $238,688,000. Marshall Wace LLP increased its position in shares of Edwards Lifesciences by 66.1% during the 4th quarter. Marshall Wace LLP now owns 5,925,627 shares of the medical research company’s stock valued at $505,160,000 after purchasing an additional 2,359,128 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in shares of Edwards Lifesciences by 221.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,060,891 shares of the medical research company’s stock valued at $167,468,000 after purchasing an additional 1,419,022 shares during the period. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president directly owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 45,577 shares of company stock valued at $3,855,527. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of NYSE:EW opened at $84.38 on Thursday. The company’s fifty day moving average is $87.65 and its two-hundred day moving average is $83.90. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a market cap of $48.59 billion, a P/E ratio of 44.88, a price-to-earnings-growth ratio of 2.12 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The business had revenue of $1.65 billion during the quarter, compared to analysts’ expectations of $1.60 billion. During the same quarter last year, the firm posted $0.64 earnings per share. Edwards Lifesciences’s revenue was up 16.7% compared to the same quarter last year. Equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on EW. TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Canaccord Genuity Group set a $85.00 target price on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Finally, BTIG Research raised their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $98.95.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.